Connect
MJA
MJA

Increase in type 2 diabetes in children and adolescents in Western Australia

Sarah K McMahon, Aveni Haynes, Nirubasini Ratnam, Maree T Grant, Christine L Carne, Timothy W Jones and Elizabeth A Davis
Med J Aust 2004; 180 (9): 459-461.
Published online: 3 May 2004

Abstract

Objectives: To document diagnosis rates of type 2 diabetes mellitus in children and adolescents in Western Australia over the past 12 years, the clinical characteristics of these patients and any comorbidities.

Design: Review of a prospectively recorded diabetes database.

Setting: Tertiary paediatric referral centre (the only such centre in WA).

Patients: All children and adolescents aged < 17 years diagnosed with type 2 diabetes between 1990 and 2002 and managed by Princess Margaret Hospital Diabetes Unit.

Main outcome measures: Anthropometric and demographic data; glycohaemoglobin (HbA1c) level; blood pressure; lipid levels; presence of acanthosis nigricans.

Results: 43 patients (15 males and 28 females) were diagnosed with type 2 diabetes. Age (SD) at diagnosis was 13.6 (1.8) years. The rate of diagnosis has been progressively increasing (average annual increase in the unadjusted overall rates of type 2 diabetes was 27%). Twenty-three patients (53%) were of Indigenous origin and 18 (42%) resided in rural areas. The mean (SD) HbA1c level at diagnosis was 10.0% (3.2%). Seventy-two per cent of patients had acanthosis nigricans, 59% had hypertension, and 24% had hyperlipidaemia.

Conclusions: There has been an increase in the diagnosis rate of type 2 diabetes in children and adolescents in WA. Comorbidities are frequent.

A recent increase in the incidence of type 2 diabetes in children and adolescents has been documented in several populations, paralleling the increase in the prevalence and degree of obesity in children and adolescents.1 Although the obesity epidemic in Australian children may also be associated with an increase in the diagnosis of type 2 diabetes, this has not yet been confirmed.

The aims of our study were to document the rates of type 2 diabetes in children and adolescents in Western Australia over the past 12 years, and to determine the clinical characteristics of these young patients and the comorbidities of type 2 diabetes in this sample.

Methods
Database

Princess Margaret Hospital for Children is the only tertiary referral hospital for children under 16 years of age with diabetes in Western Australia. Over 99% of the children with type 1 diabetes are referred to Princess Margaret Hospital.2 In addition to running metropolitan clinics, the Princess Margaret Hospital diabetes service visits 11 rural centres on a regular basis. Details of all patients managed by the service are recorded prospectively on the Western Australian Children’s Diabetes Database, regardless of diabetes type. The proportion of children with type 2 diabetes referred to the Princess Margaret Hospital diabetes service and the proportion managed by general practitioners are not known.

Subjects

All children and adolescents aged < 17 years with type 2 diabetes diagnosed between 1990 and 2002 were included in the analysis. Patient data were obtained from the database and missing information was sought from patient files. Differentiation of type 2 from type 1 diabetes was made using a combination of examination findings, anthropometry (including weight and body mass index [BMI]), the presence of acanthosis nigricans (Box 1), a family history of type 2 diabetes, C-peptide level, and an absence of autoantibodies.

Investigations and data collected

Investigations included an oral glucose tolerance test, and levels of fasting insulin, C-peptide, and glycohaemoglobin (HbA1c), as well as autoantibodies (glutamic acid decarboxylase 65 kDa isoform [GAD65] antibodies and islet-cell antibodies [ICA]).

Demographic (date of birth, sex, date of diagnosis, postcode at diagnosis, ethnicity) and anthropometric (height and weight) data were also collected, and blood pressure and lipid levels were measured. HbA1c level was measured at each clinic visit for all children from the time of diagnosis.

Hypertension was defined as systolic or diastolic blood pressure greater than the 95th centile for age, sex and height.3 Hypercholesterolaemia was defined as a total cholesterol level ≥ 5.2 mmol/L (≥ 200 mg/dL).4 HbA1c level was measured by agglutination inhibition immunoassay (Ames DCA 2000, non-insulin-dependent diabetes mellitus reference < 6.2%). BMI Z scores are calculated by subtracting the median reference value of a population from the observed value and dividing by the SD of the reference population. A Z score of 0 is equivalent to the median (50th percentile) and a Z score of 2.00 is approximately equal to the 97th percentile.

Analysis

Population statistics were obtained from Australian Bureau of Statistics census data.5,6 Estimates of the Indigenous population were made by the Epidemiology Branch of the WA Department of Health, based on 2001 census counts and adjusting annually for births and deaths. Incidence rate ratios were calculated using Poisson regression. BMI Z scores were calculated using Epi Info7 and based on 2000 Centers for Disease Control and Prevention growth charts.8

Results

A total of 43 children and adolescents aged < 17 years (15 males and 28 females) were diagnosed with type 2 diabetes at Princess Margaret Hospital between 1990 and 2002. The age (SD, median) at diagnosis was 13.6 (1.8, 13.7) years, ranging from 8.8 to 16.7 years. Twenty-three patients (53%) were of Indigenous origin and 18 (42%) resided in rural areas. The mode of presentation varied, with 5% presenting with diabetic ketoacidosis, 38% presenting with symptoms of polyuria and polydipsia, and 57% diagnosed incidentally or as part of the investigative work-up for obesity. The mean (SD) BMI Z score at diagnosis was 1.94 (0.59). The mean (SD) HbA1c level at diagnosis was 10% (3.2%). Comorbidities were common, with acanthosis nigricans found in 26/36 (72%), hypertension in 23/39 (59%) and hyperlipidaemia in 9/38 (24%) patients.

During the study period, there was an average annual increase of 27% in the unadjusted overall rates of type 2 diabetes (incidence rate ratio, 1.27; 95% CI, 1.15–1.41). This increase was highly significant in both the Indigenous and non-Indigenous groups (Box 2). Overall, the rates were higher in the Indigenous population compared with the non-Indigenous population.

Discussion

Our results suggest that there has been a significant increase in the diagnosis rate of type 2 diabetes in children and adolescents in WA, particularly over the past 7 years. The true incidence is likely to be increasing in line with the increase in obesity in our society.9 An alternative explanation for the increase in type 2 diabetes in young people is increased referral of obese children to our institution and increased screening for diabetes. However, the magnitude of the change makes this explanation unlikely. The peak age at diagnosis was between 13 and 14 years. This is also the time of peak insulin resistance during puberty.

Acanthosis nigricans is thought to be a clinical marker for hyperinsulinism (Box 1). Detection in subtle cases may be difficult, so it is possible that more than 72% of our patients had this skin finding. Acanthosis nigricans may be a useful screening tool for type 2 diabetes in obese children.

In our sample, a high proportion of patients had cardiovascular risk factors (hypertension or hyperlipidaemia) in addition to type 2 diabetes. Insulin resistance and obesity have been previously associated with both hypertension and hyperlipidaemia in children and adolescents.10 These factors, which together form the metabolic syndrome in adults, may increase the risk of cardiovascular disease in this cohort of children.

In addition to type 2 diabetes, obesity is associated with many other medical problems (apart from hypertension and hyperlipidaemia), including obstructive sleep apnoea, polycystic ovary syndrome, hepatic steatosis and orthopaedic and psychological disorders.9,10 Children and adolescents with obesity and type 2 diabetes should be assessed for the presence of these conditions when appropriate.

The increase in type 2 diabetes in children and adolescents has public health implications for Australia. Population-based strategies to increase activity, decrease sedentary behaviour and improve dietary intake are required to decrease the prevalence of overweight and obesity in our youth. Suggested strategies include setting achievable goals, involving whole families, using developmentally appropriate methods, giving education about nutrition, and incorporating increased physical activity during school hours.9 As type 2 diabetes appears to be more prevalent in the young Indigenous population, particular attention will need to be paid to this condition in preventive healthcare for Australia’s Indigenous population.

1: Acanthosis nigricans

An abnormally increased thickening and pigmentation of the skin in skinfold regions, which can be associated with obesity and high insulin levels.

2: Type 2 diabetes diagnosed each year per 100 000 population < 17 years in Western Australia

Overall incidence rate ratio (IRR), 1.27 (95% CI, 1.15–1.41).

IRR for the Indigenous group, 1.23 (95% CI, 1.07–1.40).

IRR for the non-Indigenous group, 1.31 (95% CI, 1.12–1.52).

  • Sarah K McMahon1
  • Aveni Haynes2
  • Nirubasini Ratnam3
  • Maree T Grant4
  • Christine L Carne5
  • Timothy W Jones6
  • Elizabeth A Davis7

  • Department of Endocrinology and Diabetes, Princess Margaret Hospital for Children; and Centre for Child Health Research, University of Western Australia, Telethon Institute for Child Health Research, Perth, WA.

Correspondence: 

Acknowledgements: 

We are grateful to Mr Max Bulsara for statistical advice.

Competing interests:

None identified.

  • 1. Ehtisham S, Barrett TG, Shaw NJ. Type 2 diabetes mellitus in UK children — an emerging problem. Diabet Med 2000; 17: 867-871.
  • 2. Haynes A, Bulsara M, Bowe C, et al. Continued increase in incidence of childhood onset type 1 diabetes in Western Australia (1985–2002). Australian Diabetes Society Annual Scientific Meeting; 2003 Sep 17–19; Melbourne. Melbourne: Australian Diabetes Society, 2003: 64.
  • 3. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents [comment]. Pediatrics 1996; 98: 649-658.
  • 4. Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care 2003; 26: 2194-2197.
  • 5. Australian Bureau of Statistics. Estimated resident population by age and sex in statistical local areas, Western Australia (1985–2001). Canberra: ABS, 2001. (Catalogue No. 3203.5.)
  • 6. Australian Bureau of Statistics. Population by age and sex, Western Australia. Canberra: ABS, 2002. (Catalogue No. 3235.5.)
  • 7. Epi Info [computer program] 2002. Revision 2nd ed. US Department of Health and Human Services, Centers for Disease Control and Prevention, Epidemiology Program Office, Division of Public Health Surveillance and Informatics, 2002.
  • 8. 2000 CDC growth charts: United States. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2000. Available at: www.cdc.gov/growthcharts/ (accessed Mar 2004).
  • 9. Baur LA. Child and adolescent obesity in the 21st century: an Australian perspective. Asia Pac J Clin Nutr 2002; 11 Suppl 3: S524-S528.
  • 10. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 2003; 107: 1448-1453.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.